181 related articles for article (PubMed ID: 20139722)
1. An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo.
Cherrin C; Haskell K; Howell B; Jones R; Leander K; Robinson R; Watkins A; Bilodeau M; Hoffman J; Sanderson P; Hartman G; Mahan E; Prueksaritanont T; Jiang G; She QB; Rosen N; Sepp-Lorenzino L; Defeo-Jones D; Huber HE
Cancer Biol Ther; 2010 Apr; 9(7):493-503. PubMed ID: 20139722
[TBL] [Abstract][Full Text] [Related]
2. BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.
Politz O; Siegel F; Bärfacker L; Bömer U; Hägebarth A; Scott WJ; Michels M; Ince S; Neuhaus R; Meyer K; Fernández-Montalván AE; Liu N; von Nussbaum F; Mumberg D; Ziegelbauer K
Int J Cancer; 2017 Jan; 140(2):449-459. PubMed ID: 27699769
[TBL] [Abstract][Full Text] [Related]
3. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
[TBL] [Abstract][Full Text] [Related]
4. Tirucallic acids are novel pleckstrin homology domain-dependent Akt inhibitors inducing apoptosis in prostate cancer cells.
Estrada AC; Syrovets T; Pitterle K; Lunov O; Büchele B; Schimana-Pfeifer J; Schmidt T; Morad SA; Simmet T
Mol Pharmacol; 2010 Mar; 77(3):378-87. PubMed ID: 20018812
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Prostate Cancer DU-145 Cells Proliferation by
Li X; Tang Y; Yu F; Sun Y; Huang F; Chen Y; Yang Z; Ding G
Mar Drugs; 2018 Sep; 16(9):. PubMed ID: 30208576
[TBL] [Abstract][Full Text] [Related]
6. Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors.
Edgar KA; Wallin JJ; Berry M; Lee LB; Prior WW; Sampath D; Friedman LS; Belvin M
Cancer Res; 2010 Feb; 70(3):1164-72. PubMed ID: 20103642
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of celastrol by inhibition of proliferation, invasion, and migration in cholangiocarcinoma via PTEN/PI3K/Akt pathway.
Zhu B; Wei Y
Cancer Med; 2020 Jan; 9(2):783-796. PubMed ID: 31957323
[TBL] [Abstract][Full Text] [Related]
9. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.
Davies BR; Greenwood H; Dudley P; Crafter C; Yu DH; Zhang J; Li J; Gao B; Ji Q; Maynard J; Ricketts SA; Cross D; Cosulich S; Chresta CC; Page K; Yates J; Lane C; Watson R; Luke R; Ogilvie D; Pass M
Mol Cancer Ther; 2012 Apr; 11(4):873-87. PubMed ID: 22294718
[TBL] [Abstract][Full Text] [Related]
10. Hydrazinocurcumin and 5-fluorouracil enhance apoptosis and restrain tumorigenicity of HepG2 cells via disrupting the PTEN-mediated PI3K/Akt signaling pathway.
Zhou Y; Zhang M; Zhang Z; Jia Y; Zhang C; Peng L
Biomed Pharmacother; 2020 Sep; 129():109851. PubMed ID: 32559627
[TBL] [Abstract][Full Text] [Related]
11. Allosteric inhibitors of Akt1 and Akt2: a naphthyridinone with efficacy in an A2780 tumor xenograft model.
Bilodeau MT; Balitza AE; Hoffman JM; Manley PJ; Barnett SF; Defeo-Jones D; Haskell K; Jones RE; Leander K; Robinson RG; Smith AM; Huber HE; Hartman GD
Bioorg Med Chem Lett; 2008 Jun; 18(11):3178-82. PubMed ID: 18479914
[TBL] [Abstract][Full Text] [Related]
12. 1,25-dihydroxyvitamin D(3) and PI3K/AKT inhibitors synergistically inhibit growth and induce senescence in prostate cancer cells.
Axanova LS; Chen YQ; McCoy T; Sui G; Cramer SD
Prostate; 2010 Nov; 70(15):1658-71. PubMed ID: 20583132
[TBL] [Abstract][Full Text] [Related]
13. AKT1-CREB stimulation of PDGFRα expression is pivotal for PTEN deficient tumor development.
Wan X; Zhou M; Huang F; Zhao N; Chen X; Wu Y; Zhu W; Ni Z; Jin F; Wang Y; Hu Z; Chen X; Ren M; Zhang H; Zha X
Cell Death Dis; 2021 Feb; 12(2):172. PubMed ID: 33568640
[TBL] [Abstract][Full Text] [Related]
14. Reactive nitrogen species induced by hyperglycemia suppresses Akt signaling and triggers apoptosis by upregulating phosphatase PTEN (phosphatase and tensin homologue deleted on chromosome 10) in an LKB1-dependent manner.
Song P; Wu Y; Xu J; Xie Z; Dong Y; Zhang M; Zou MH
Circulation; 2007 Oct; 116(14):1585-95. PubMed ID: 17875968
[TBL] [Abstract][Full Text] [Related]
15. The LXR-623-induced long non-coding RNA LINC01125 suppresses the proliferation of breast cancer cells via PTEN/AKT/p53 signaling pathway.
Wan W; Hou Y; Wang K; Cheng Y; Pu X; Ye X
Cell Death Dis; 2019 Mar; 10(3):248. PubMed ID: 30867411
[TBL] [Abstract][Full Text] [Related]
16. Impact of lipid phosphatases SHIP2 and PTEN on the time- and Akt-isoform-specific amelioration of TNF-alpha-induced insulin resistance in 3T3-L1 adipocytes.
Ikubo M; Wada T; Fukui K; Ishiki M; Ishihara H; Asano T; Tsuneki H; Sasaoka T
Am J Physiol Endocrinol Metab; 2009 Jan; 296(1):E157-64. PubMed ID: 19001549
[TBL] [Abstract][Full Text] [Related]
17. Chronic and Intermittent Hyperglycemia Modulates Expression of Key Molecules of PI3K/AKT Pathway in Differentiating Human Visceral Adipocytes.
Świderska E; Strycharz J; Wróblewski A; Czarny P; Szemraj J; Drzewoski J; Śliwińska A
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299331
[TBL] [Abstract][Full Text] [Related]
18. Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo.
Luo Y; Shoemaker AR; Liu X; Woods KW; Thomas SA; de Jong R; Han EK; Li T; Stoll VS; Powlas JA; Oleksijew A; Mitten MJ; Shi Y; Guan R; McGonigal TP; Klinghofer V; Johnson EF; Leverson JD; Bouska JJ; Mamo M; Smith RA; Gramling-Evans EE; Zinker BA; Mika AK; Nguyen PT; Oltersdorf T; Rosenberg SH; Li Q; Giranda VL
Mol Cancer Ther; 2005 Jun; 4(6):977-86. PubMed ID: 15956255
[TBL] [Abstract][Full Text] [Related]
19. Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling.
She QB; Chandarlapaty S; Ye Q; Lobo J; Haskell KM; Leander KR; DeFeo-Jones D; Huber HE; Rosen N
PLoS One; 2008 Aug; 3(8):e3065. PubMed ID: 18725974
[TBL] [Abstract][Full Text] [Related]
20. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts.
Wu L; Birle DC; Tannock IF
Cancer Res; 2005 Apr; 65(7):2825-31. PubMed ID: 15805283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]